Fimasartan Ameliorates Deteriorations in Glucose Metabolism in a High Glucose State by Regulating Skeletal Muscle and Liver Cells

키워드

참고문헌 (45)

1. Chellan N, "An in vitro assessment of the effect of Athrixia phylicoides DC. aqueous extract on glucose metabolism", Phytomedicine, 19, pp.730~736 (2012)
2. Tisch R, "Insulin-dependent diabetes mellitus", Cell, 85, pp.291~297 (1996)
3. Hales CN, "Type 2(non-insulin-dependent)diabetes mellitus : the thrifty phenotype hypothesis", Diabetologia, 35, pp.595~601 (1992)
4. Horr S, "Managing hypertension in type 2 diabetes mellitus", Best Pract Res Clin Endocrinol Metab, 30, pp.445~454 (2016)
5. UK Prospective Diabetes Study Group, "Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38", BMJ, 317, pp.703~713 (1998)
6. Tatsumi Y, "Hypertension with diabetes mellitus : significance from an epidemiological perspective for Japanese", Hypertens Res, 40, pp.795~806 (2017)
7. Kim JH, "Fimasartan, a novel angiotensin II receptor antagonist", Arch Pharm Res, 35, pp.1123~1126 (2012)
8. Karnik SS, "International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin receptors : interpreters of pathophysiological angiotensinergic stimuli", Pharmacol Rev, 67, pp.754~819 (2015)
9. Chrysant SG, "The pleiotropic effects of angiotensin receptor blockers", J Clin Hypertens(Greenwich), 8, pp.261~268 (2006)
10. Savoia C, "Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients", Hypertension, 49, pp.341~346 (2007)
11. Sica DA, "Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study(LIFE) : a randomised trial against atenolol", Curr Hypertens Rep, 4, pp.321~323 (2002)
12. Smith AG, "Skeletal muscle and nuclear hormone receptors : implications for cardiovascular and metabolic disease", Int J Biochem Cell Biol, 37, pp.2047~2063 (2005)
13. Kelley DE, "Muscle triglyceride and insulin resistance", Annu Rev Nutr, 22, pp.325~346 (2002)
14. Nordlie RC, "Regulation of glucose production by the liver", Annu Rev Nutr, 19, pp.379~406 (1999)
15. Prasannarong M, "ANG-(1-7)reduces ANG II-induced insulin resistance by enhancing Akt phosphorylation via a Mas receptor-dependent mechanism in rat skeletal muscle", Biochem Biophys Res Commun, 426, pp.369~373 (2012)
16. Favre GA, "Modulation of glucose metabolism by the renin-angiotensin-aldosterone system", Am J Physiol Endocrinol Metab, 308, pp.E435~E449 (2015)
17. Furuhashi M, "Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension", Hypertension, 42, pp.76~81 (2003)
18. Shiota A, "Telmisartan ameliorates insulin sensitivity by activating the AMPK", SIRT1 pathway in skeletal muscle of obese db, Cardiovasc Diabetol, pp.2012, 11[DOI]
19. Lee YJ, "Fimasartan ameliorates nonalcoholic fatty liver disease through PPARδ regulation in hyperlipidemic and hypertensive conditions", PPAR Res, 2017, pp.8048720~ (2017)
20. Kim S, "Fimasartan, a novel angiotensin-receptor blocker, protects against renal inflammation and fibrosis in mice with unilateral ureteral obstruction : the possible role of Nrf2", Int J Med Sci, 12, pp.891~904 (2015)
21. Yang XL, "Anti-inflammatory effects of fimasartan via Akt, ERK, and NFκB pathways on astrocytes stimulated by hemolysate", Inflamm Res, 65, pp.115~123 (2016)
22. De Taeye BM, "Macrophage TNF-α contributes to insulin resistance and hepatic steatosis in diet-induced obesity", Am J Physiol Endocrinol Metab, 293, pp.E713~E725 (2007)
23. Yang YS, "Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine", Diabetes Obes Metab, 20, pp.1670~1677 (2018)
24. Long YC, "Insulin receptor substrates Irs1 and Irs2 coordinate skeletal muscle growth and metabolism via the Akt and AMPK pathways", Mol Cell Biol, 31, pp.430~441 (2011)
25. Zhang BB, "AMPK : an emerging drug target for diabetes and the metabolic syndrome", Cell Metab, 9, pp.407~416 (2009)
26. Reilly SM, "PPAR delta as a therapeutic target in metabolic disease", FEBS Lett, 582, pp.26~31 (2008)
27. Woods A, "Identification of phosphorylation sites in AMP-activated protein kinase(AMPK)for upstream AMPK kinases and study of their roles by site-directed mutagenesis", J Biol Chem, 278, pp.28434~28442 (2003)
28. Rutter GA, "Roles of 5'-AMP-activated protein kinase(AMPK)in mammalian glucose homoeostasis", Biochem J, 375, pp.1~16 (2003)
29. Cho MC, "Peroxisome proliferators-activated receptor(PPAR)modulators and metabolic disorders", PPAR Res, 2008, pp.679137~ (2008)
30. Monsalve FA, "Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases", Mediators Inflamm, 2013, pp.549627~ (2013)
31. Schupp M, "Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity", Circulation, 109, pp.2054~2057 (2004)
32. Tontonoz P, "mPPAR gamma 2 : tissue-specific regulator of an adipocyte enhancer", Genes Dev, 8, pp.1224~1234 (1994)
33. Krämer DK, "Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle", J Biol Chem, 282, pp.19313~19320 (2007)
34. Luquet S, "Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability", FASEB J, 17, pp.2299~2301 (2003)
35. Lowell BB, "Mitochondrial dysfunction and type 2 diabetes", Science, 307, pp.384~387 (2005)
36. Rong JX, "Adipose mitochondrial biogenesis is suppressed in db", db and high-fat dietfed mice and improved by rosiglitazone, 2007, pp.56, 1751~1760
37. Short KR, "Decline in skeletal muscle mitochondrial function with aging in humans", Proc Natl Acad Sci U S A, 102, pp.5618~5623 (2005)
38. McInnes J, "Mitochondrial-associated metabolic disorders: foundations, pathologies and recent progress", Nutr Metab (Lond), 10, pp.63~ (2013)
39. Gan Z, "The nuclear receptor PPARβ", δ programs muscle glucose metabolism in cooperation with AMPK and MEF2, 2011, pp.25, 2619~2630
40. Hartman ML, "Relation of mitochondrial oxygen consumption in peripheral blood mononuclear cells to vascular function in type 2 diabetes mellitus", Vasc Med, 19, pp.67~74 (2014)
41. Akatsuka A, "Comparison of the liver glycogen synthase from normal and streptozotocin-induced diabetic rats", Arch Biochem Biophys, 220, pp.426~434 (1983)
42. 한혜숙, "Regulation of glucose metabolism from a liver-centric perspective", Experimental and Molecular Medicine, 48, pp.1~10 (2016), 생화학분자생물학회
43. Mårin P, "Glucose uptake in human adipose tissue", Metabolism, 36, pp.1154~1160 (1987)
44. Feng X, "Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ", AMPK pathway, 2011, pp.15, 1572~1581
45. Amoghimath S, "Effect of telmisartan on blood glucose levels and blood lipid levels in streptozotocin induced diabetic rats", Biomed Pharmacol J, 12, pp.1303~1308 (2019)

관련 논문AI추천